Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 100441 | 3.875 |
09:34 ET | 28181 | 3.86 |
09:36 ET | 2142 | 3.865 |
09:38 ET | 2191 | 3.87 |
09:39 ET | 234922 | 3.87 |
09:41 ET | 17064 | 3.88 |
09:43 ET | 24771 | 3.875 |
09:45 ET | 42169 | 3.885 |
09:48 ET | 112403 | 3.895 |
09:50 ET | 32125 | 3.89 |
09:52 ET | 103877 | 3.87 |
09:54 ET | 17852 | 3.875 |
09:56 ET | 53465 | 3.875 |
09:57 ET | 12506 | 3.86 |
09:59 ET | 4000 | 3.87 |
10:01 ET | 24264 | 3.865 |
10:03 ET | 58490 | 3.87 |
10:06 ET | 120385 | 3.865 |
10:08 ET | 16827 | 3.865 |
10:10 ET | 4995 | 3.865 |
10:12 ET | 16273 | 3.85 |
10:14 ET | 27889 | 3.86 |
10:15 ET | 45196 | 3.86 |
10:17 ET | 7067 | 3.865 |
10:19 ET | 28427 | 3.85 |
10:21 ET | 6658 | 3.86 |
10:24 ET | 3106 | 3.855 |
10:26 ET | 55700 | 3.865 |
10:28 ET | 4304 | 3.86 |
10:30 ET | 12484 | 3.85 |
10:32 ET | 133026 | 3.845 |
10:33 ET | 9038 | 3.85 |
10:35 ET | 13631 | 3.86 |
10:37 ET | 3200 | 3.855 |
10:39 ET | 15850 | 3.845 |
10:42 ET | 10062 | 3.85 |
10:44 ET | 6684 | 3.85 |
10:46 ET | 12683 | 3.865 |
10:48 ET | 25790 | 3.845 |
10:50 ET | 6756 | 3.85 |
10:51 ET | 5756 | 3.85 |
10:53 ET | 12766 | 3.85 |
10:55 ET | 15747 | 3.85 |
10:57 ET | 10014 | 3.845 |
11:00 ET | 16574 | 3.85 |
11:02 ET | 42182 | 3.845 |
11:04 ET | 57093 | 3.8301 |
11:06 ET | 20285 | 3.8318 |
11:08 ET | 26134 | 3.835 |
11:09 ET | 2223 | 3.83 |
11:11 ET | 9700 | 3.84 |
11:13 ET | 13150 | 3.835 |
11:15 ET | 7618 | 3.8312 |
11:18 ET | 700 | 3.835 |
11:20 ET | 5862 | 3.835 |
11:22 ET | 14460 | 3.835 |
11:24 ET | 2236 | 3.835 |
11:26 ET | 7435 | 3.835 |
11:27 ET | 25883 | 3.84 |
11:29 ET | 17917 | 3.84 |
11:31 ET | 21898 | 3.845 |
11:33 ET | 36838 | 3.845 |
11:36 ET | 10680 | 3.84 |
11:38 ET | 5238 | 3.8375 |
11:40 ET | 21861 | 3.86 |
11:42 ET | 2513 | 3.855 |
11:44 ET | 10870 | 3.85 |
11:45 ET | 1865 | 3.85 |
11:47 ET | 2886 | 3.85 |
11:49 ET | 3342 | 3.85 |
11:51 ET | 3900 | 3.855 |
11:54 ET | 1598 | 3.85 |
11:56 ET | 3184 | 3.85 |
11:58 ET | 2342 | 3.85 |
12:00 ET | 1791 | 3.85 |
12:02 ET | 1592 | 3.85 |
12:03 ET | 4634 | 3.855 |
12:05 ET | 6800 | 3.85 |
12:07 ET | 1850 | 3.85 |
12:09 ET | 1500 | 3.85 |
12:12 ET | 3600 | 3.85 |
12:14 ET | 1200 | 3.85 |
12:16 ET | 3118 | 3.853 |
12:18 ET | 2722 | 3.85 |
12:20 ET | 2584 | 3.85 |
12:21 ET | 6870 | 3.853 |
12:23 ET | 6000 | 3.85 |
12:25 ET | 3300 | 3.855 |
12:27 ET | 3950 | 3.853 |
12:30 ET | 19466 | 3.855 |
12:32 ET | 73672 | 3.85 |
12:34 ET | 2281 | 3.853 |
12:36 ET | 628 | 3.85 |
12:38 ET | 1333 | 3.855 |
12:39 ET | 18173 | 3.865 |
12:43 ET | 2335 | 3.865 |
12:45 ET | 1200 | 3.865 |
12:48 ET | 4981 | 3.865 |
12:50 ET | 2165 | 3.863 |
12:52 ET | 2183 | 3.865 |
12:54 ET | 1400 | 3.86 |
12:56 ET | 4886 | 3.865 |
12:57 ET | 1380 | 3.865 |
12:59 ET | 1700 | 3.865 |
01:01 ET | 14045 | 3.8501 |
01:03 ET | 17592 | 3.85 |
01:06 ET | 2017 | 3.855 |
01:08 ET | 1095 | 3.855 |
01:10 ET | 1634 | 3.855 |
01:12 ET | 101099 | 3.855 |
01:14 ET | 6002 | 3.855 |
01:15 ET | 2014 | 3.855 |
01:17 ET | 2716 | 3.8513 |
01:19 ET | 1488 | 3.86 |
01:21 ET | 59933 | 3.855 |
01:24 ET | 600 | 3.85 |
01:26 ET | 66470 | 3.85 |
01:28 ET | 4423 | 3.855 |
01:30 ET | 600 | 3.85 |
01:32 ET | 400 | 3.852 |
01:33 ET | 3600 | 3.85 |
01:35 ET | 700 | 3.85 |
01:37 ET | 4703 | 3.855 |
01:39 ET | 2000 | 3.855 |
01:42 ET | 1354 | 3.8521 |
01:44 ET | 3276 | 3.85 |
01:46 ET | 3129 | 3.855 |
01:48 ET | 3100 | 3.85 |
01:50 ET | 1567 | 3.85 |
01:51 ET | 3827 | 3.855 |
01:53 ET | 3672 | 3.855 |
01:55 ET | 22450 | 3.852 |
01:57 ET | 2542 | 3.85 |
02:00 ET | 17059 | 3.853 |
02:02 ET | 800 | 3.85 |
02:04 ET | 900 | 3.853 |
02:06 ET | 1800 | 3.855 |
02:08 ET | 3288 | 3.85 |
02:09 ET | 42860 | 3.865 |
02:11 ET | 8000 | 3.865 |
02:13 ET | 22317 | 3.875 |
02:15 ET | 6400 | 3.875 |
02:18 ET | 12525 | 3.885 |
02:20 ET | 6281 | 3.885 |
02:22 ET | 800 | 3.885 |
02:24 ET | 5504 | 3.885 |
02:26 ET | 628 | 3.89 |
02:27 ET | 6700 | 3.8801 |
02:29 ET | 6489 | 3.882 |
02:31 ET | 34065 | 3.885 |
02:33 ET | 11181 | 3.88 |
02:36 ET | 20141 | 3.88 |
02:38 ET | 619 | 3.885 |
02:40 ET | 15700 | 3.88 |
02:42 ET | 4617 | 3.885 |
02:44 ET | 12778 | 3.881 |
02:45 ET | 500 | 3.88 |
02:47 ET | 8100 | 3.88 |
02:49 ET | 1903 | 3.881 |
02:51 ET | 6066 | 3.88 |
02:54 ET | 1193 | 3.885 |
02:56 ET | 1300 | 3.89 |
02:58 ET | 980 | 3.88 |
03:00 ET | 1858 | 3.88 |
03:02 ET | 3300 | 3.88 |
03:03 ET | 1000 | 3.88 |
03:05 ET | 15135 | 3.88 |
03:07 ET | 45081 | 3.885 |
03:09 ET | 900 | 3.885 |
03:12 ET | 400 | 3.88 |
03:14 ET | 3880 | 3.885 |
03:16 ET | 1200 | 3.885 |
03:18 ET | 1227 | 3.885 |
03:20 ET | 20278 | 3.9 |
03:21 ET | 4237 | 3.9 |
03:23 ET | 96825 | 3.905 |
03:25 ET | 5448 | 3.905 |
03:27 ET | 4655 | 3.905 |
03:30 ET | 43939 | 3.91 |
03:32 ET | 33158 | 3.91 |
03:34 ET | 6738 | 3.905 |
03:36 ET | 46260 | 3.915 |
03:38 ET | 26190 | 3.92 |
03:39 ET | 23909 | 3.92 |
03:41 ET | 28072 | 3.92 |
03:43 ET | 20264 | 3.92 |
03:45 ET | 10230 | 3.92 |
03:48 ET | 162775 | 3.915 |
03:50 ET | 100353 | 3.9 |
03:52 ET | 66607 | 3.9 |
03:54 ET | 12063 | 3.9 |
03:56 ET | 78781 | 3.895 |
03:57 ET | 96223 | 3.9 |
03:59 ET | 478037 | 3.9 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.3B | -11.3x | --- |
Vera Therapeutics Inc | 2.3B | -20.5x | --- |
Rocket Pharmaceuticals Inc | 2.1B | -8.2x | --- |
Janux Therapeutics Inc | 2.5B | -38.8x | --- |
Dyne Therapeutics Inc | 2.6B | -7.3x | --- |
Sana Biotechnology Inc | 2.1B | -5.6x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.3B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -11.3x |
Price/Sales (TTM) | 4,448.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.